Lutter to fill in for Gottlieb as acting FDA policy head

Share this article:
FDA commissioner Andrew von Eschenbach named Randall Lutter to serve as acting deputy commissioner for policy, replacing Dr. Scott Gottlieb, who leaves the agency Jan. 16 to rejoin the American Enterprise Institute (AEI). Lutter was most recently associate commissioner of policy and planning. Before he joined the FDA in 2003 as chief economist in the office of planning, he was a resident scholar at AEI and a fellow with the AEI-Brookings Joint Center for Regulatory Studies. His recent works include a study on the impact of accelerated approval times on pharmaceutical R&D investment, which concluded that PDUFA contributed $13.5 billion to R&D spending from 1992 to 2001, and a study on how routine genetic screening might improve outcomes in patients on warfarin (coumadin).
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.